Stock Update (NASDAQ:MNKD): MannKind Corporation and Charles Mattocks Announce “REVERSED”-America’s First Docu-Series Tackling Diabetes

MannKind Corporation (NASDAQ:MNKD) and Bella & Elle Media LLC announce MannKind’s sponsorship of “Reversed,” a production series aimed at educating the show’s participants and viewing audience about the effects of poorly managed diabetes and its impact on their lives.  “Reversed” will air on Discovery Life Channel in the summer of 2017.

“Reversed” was created by Celebrity Chef and Diabetes Advocate, Charles Mattocks.  The award-winning producer and bestselling author will host “Reversed,” as it follows the lives of individuals affected by diabetes and their struggle to change their diet, exercise and mindset about the disease.  “Reversed” will feature experts such as diabetes educators, endocrinologists, therapists, nutritionists, and trainers, as well as celebrity guests who are also living with diabetes, to help encourage the contestants.

Charles Mattocks, nephew of legendary Bob Marley, said, “My uncle made an impact on the world through music and my vision is to impact health. ‘Reversed’ is about changing the behavior of those with diabetes. I am excited that MannKind has joined ‘Reversed’ in our mission.”

Michael Castagna, Chief Commercial Officer of MannKind Corporation, added, “MannKind is continually seeking platforms to increase awareness around the challenges, opportunities and success people living with diabetes encounter on a daily basis.  Mr. Mattock’s educational platforms, which have been featured on CNN, Dr. Oz and The Today Show, showcase the strength and determination of people fighting to make their lives better as they fight diabetes.  We are excited to be associated with Mr. Mattock’s continuing efforts to educate the public.”

Shares of MannKind closed yesterday at $1.97, up $0.08 or 4.23%. MNKD has a 1-year high of $11.20 and a 1-year low of $1.74. The stock’s 50-day moving average is $0.70 and its 200-day moving average is $0.64.

On the ratings front, J.P. Morgan analyst Cory Kasimov reiterated a Sell rating on MNKD, in a report issued on November 10. According to, Kasimov has a yearly average loss of 6.4%, a 40% success rate, and is ranked #4350 out of 4513 analysts.

MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer.


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts